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Abstract 
Background: Brain‑derived neurotrophic factor (BDNF) has been reported to affect development, cognition, atten‑
tion and behavior. However, few studies have investigated preschool children with regard to these areas. We evalu‑
ated the relationship between cognition, attention and peripheral blood concentration of BDNF in preschool children.
Methods: Twenty‑eight children (mean age: 6.16 ± 0.60 years) were recruited. For all subjects, serum and plasma 
BDNF levels were assessed; intelligence was assessed using the Korean standardisation of the Wechsler Intelligence 
Scale for Children (KEDI‑WISC); attention was assessed using the computerised continuous performance test (CCPT), 
the children’s color trails test (CCTT), the Stroop color‑word test for preschool children, and the attention‑deficit/
hyperactivity disorder rating scale (K‑ARS); and finally emotional and behavioral problems were assessed using the 
child behavior checklist (K‑CBCL). We confirmed the previously reported correlations between the various psychomet‑
ric properties assessed and serum and plasma levels of BDNF in our sample.
Results: Serum BDNF levels were negatively correlated with both KEDI‑WISC full scale IQ (FSIQ, r = −0.39, p = 0.04) 
and verbal IQ (VIQ, r = −0.05, p = 0.01), but not with the performance IQ (PIQ, r = −0.12, p = 0.56). There were no 
significant relationships between plasma BDNF level and VIQ, PIQ or FSIQ. No correlations were found between either 
serum or plasma level of BDNF and any of the attentional measures (CCPT, ARS, CCTT or Stroop color word test). The 
CBCL total behavioral problem and attention problem sections were positively correlated with plasma BDNF level 
(r = 0.41, p = 0.03), (r = 0.44, p = 0.02), however, no relationship was found between the serum BDNF and any of the 
composite CBCL measures.
Conclusions: Our results suggest that high peripheral BDNF may be negatively correlated with intelligence, behav‑
ioral problems and clinical symptoms of neuro‑developmental disorders such as intellectual disability in preschool 
children. A high peripheral BDNF concentration may, if these findings are further replicated, prove to be a useful 
biomarker for such issues in preschool children.
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Background
Brain-derived neurotrophic factor (BDNF) is a member 
of the neurotrophin family, which is expressed in human 
and other mammalian brains [1]. BDNF is associated 
with synaptic plasticity, synaptic connectivity formation 
and neuronal survival [2–4]. It also serves an important 
role during brain development [3] through the regula-
tion of neural circuit development by selective embry-
onic neural stem cell survival and differentiation, axonal 
growth and guidance, synapse formation and maturation, 
and the refinement of developing circuits [4].
BDNF plays an important role in learning and memory 
[5–7]. Several reports relate BDNF levels to task perfor-
mance in cognitive assessment of the rat [8–10]. Admin-
istration of BDNF enhances rat performance in the 
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Morris water maze (MWM) [8], while injection of BDNF 
antibodies into their lateral ventricles is correlated with 
poorer MWM performance [9]. However, Cunha et  al. 
[10] have suggested that chronic BDNF over-expression 
in young adult transgenic mice (9–14  week) can induce 
learning deficits and short-term memory impairment on 
both spatial and instrumental learning tasks.
A number of reports suggest a relationship between 
BDNF and the functioning of certain brain areas involved 
in attention and cognition [11–15]. The highest levels of 
CNS BDNF are found in the hippocampus, frontal cor-
tex, and amygdale [11, 12]. Both endogenous BDNF and 
intra-hippocampal BDNF infusion induce hippocampal 
long-term potentiation, which is critical to the physiology 
of long-term memory formation [13, 14]. BDNF plays an 
important role in the working memory of the prefrontal 
cortex [15].
Currently, most research on the interrelationships 
between mood, psychosis, cognition, attention and 
peripheral BDNF concentration has been conducted 
with adults [16–21]. Relatively little research on the asso-
ciations among attention, cognition, development and 
peripheral BDNF levels have been conducted with chil-
dren [22–26].
We evaluated the relationships among cognition, atten-
tion and peripheral blood BDNF concentrations in chil-
dren. CNS BDNF crosses the blood-brain-barrier into 
the peripheral blood [27]. Some reports suggest that 
serum and cortical BDNF levels are positively correlated 
and that plasma BDNF levels directly reflect brain tissue 
levels [28, 29].
In the present study, we have assessed serum and 
plasma BDNF levels, preschool child IQ, inattention, 
hyperactivity, internalized/externalized problems, behav-




Twenty-eight preschool children [13 boys, 15 girls, mean 
age: 6.16 ± 0.60 years (age range 5–7 years)] who lived in 
Ulsan metropolitan city in Korea were recruited for this 
study by advertisements in the Ulsan University Hospi-
tal. This study was approved by the Institutional Review 
Board of the Ulsan University Hospital. In accordance 
with the Declaration of Helsinki, both the subjects and 
their parents were advised the procedure. Parents of the 
subject were required to provide written informed con-
sent prior to participation in the study. The demographic 
variables of the participants were composed of mater-
nal age at pregnancy, birth weight, paternal education, 
maternal education, income, and secondhand smoke 
exposure.
Psychometric properties
To test intelligence, we administered the Korean Edu-
cational Development Institute’s Wechsler Intelligence 
Scale for Children (KEDI-WISC). The average KEDI-
WISC is 100 ± 15 [30].
Sustained attention, vigilance and distractibility were 
assessed by the computerized continuous performance 
test (CCPT). The Korean version of the CCPT is a diag-
nostic tool of attention deficit-hyperactivity disorder and 
has acquired validity and reliability [31]. CCPT comprises 
an auditory and visual test that records omission error, 
commission error, response time and standard deviations 
of response time. If a T-score is more than 65 in any of 
these variables, ADHD is suspicious [32].
The children’s color trails test (CCTT) is the children’s 
version of the color trails test. The CCTT assesses fron-
tal lobe function, including visual-motor coordination, 
attention, and cognitive flexibility [33]. The Korean ver-
sion was standardized by Koo and Shin [34]. This test 
scores the total time to finish (CCTT 1 and CCTT 2) 
and the difference interference index (total time to fin-
ish CCTT 1- total time to finish CCTT 2) [34]. The mean 
T-score of the CCTT is 50  ±  10 [35]. Higher T-scores 
indicate better performance on the test [35].
The Stroop color-word test assesses cognitive inhibi-
tion and the ability to ignore the interference from irrel-
evant stimuli [36]. The Korean version of the Stroop 
color-word test has been standardized [37]. The average 
T-score of the Stroop color word test is 50 ± 10 [37].
The Korean parent-report version of the child behavior 
checklist (CBCL) was used to assess child emotional and 
behavioral problems. This version of the CBCL [38, 39] is 
a 121-item questionnaire measure which is widely used 
in Korea. Each item is scored from 0 (absent) to 2 (very 
often present), and composite scores for each subscale 
are then converted to give T-scores with a mean of 50 and 
SD of 10 [38]. Five subscale scores were used to profile 
results in the present study, namely internalizing prob-
lems; externalizing problems; total behavior problems; 
anxiety/depression and attention problems. The exter-
nalizing problems of the K-CBCL comprise attention 
problems and aggressive and delinquent behavior. The 
internalizing problems consist of withdrawal; depressed 
behavior; and somatic complaints [40]. For diagnosis of 
ADHD, the positive predictive value and specificity of the 
attention problem section is significant when the child 
achieves a T-score ≥60, and when the total problem sec-
tion yields a T-score ≥63 [40].
ADHD screening and symptom severity was assessed 
by the standardized Korean version of attention deficit 
hyperactivity disorder rating scale (ARS) [41, 42]. ARS is 
based on DSM-IV criteria and parent or teacher report. 
The ARS contains 18 items that include nine inattention 
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relatedness and nine hyperactivity and impulsivity fac-
tors. Each item score ranges from 0 (never) to 3 (very 
often). Therefore, the total range of score is 0 to 54. A 
reasonable level of sensitivity, specificity and negative 
predictive value for the diagnosis of ADHD is acquired 
when the ARS total score is more than 14.5–15.5 [40]. A 
higher score indicates more severe problems [41].
Blood BDNF drawing
Blood samples were drawn from all participants at 2 pm. 
For the serum BDNF analysis, we used a serum separator 
tube (SST) and allowed samples to clot for 30 min before 
centrifugation for 15 min at approximately 1000×g. The 
serum was removed, and the separated serum layer was 
aliquoted into 5-ml polypropylene cryo-vialsand stored 
at −80  °C until assay analysis. Plasma was collected on 
ice using EDTA tubes and centrifuged for 15  min at 
1000×g at 4 °C within 30 min of collection. An additional 
centrifugation step was conducted on the separated 
plasma at 10,000×g for 10 min at 4 °C, as recommended 
for complete platelet removal. We removed the plasma, 
and the separated plasma layer was aliquoted into 5-ml 
polypropylene cryo-vials and stored at −80 °C until assay 
analysis. The samples were diluted with diluent included 
in the R&D Human BDNF Quantikine ELISA kit (Min-
neapolis, Minnesota) to bring measured levels of BDNF 
within the range of the standard provided. The results are 
reported in pg/ml.
Statistical analyses
All statistical analyses were performed with SPSS ver-
sion 17.0 for windows. The demographic variables (age, 
maternal age at onset, birth weight, paternal, maternal 
education, income, indirect smoking) and psychometric 
properties (IQ, CCPT, CCTT, Stroop test, CBCL, ARS) 
of the participants, were ascertained by descriptive statis-
tics. Serum and plasma levels of BDNF were compared to 
reference values. A two-tailed Pearson χ2 test was used to 
establish the level of correlation between the psychomet-
ric scores and serum and plasma BDNF levels. Statistical 
significance was reported for results above the 0.05 level.
Results
Result of variables
Demographic data are shown in Table  1. A total of 28 
children [13 boys (46 % of participants) and, 15 girls (54 % 
of participants)] were recruited. Most parents of the 
participants had been educated for more than 12  years 
(82.1 %). The psychometric properties of participants are 
shown in Table 2. The mean full scale IQ of the partici-
pants was 106.89 ± 12.41. The mean CBCL scores were 
as follows: internalizing problems (45.64 ± 10.31), exter-
nalizing problems (48.54 ± 7.34), total behavior problems 
(46.68  ±  9.55), anxiety/depression (46.64  ±  9.83), and 
attention problems (43.86 ± 7.71). The mean ARS score 
was 6.04 ±  5.82. Serum or plasma BDNF levels did not 
differ statistically across the sexes or with age. Addition-
ally, there were no differences in psychometric scores 
across the sexes or with age, except for the CCPT com-
mission error (visual) (p =  0.02) and ARS hyperactivity 
(p = 0.04), inattention (p = 0.005), total (p = 0.03) scores, 
which showed gender differences.
Correlations with peripheral BDNF concentration 
and psychometric properties
We examined correlations with the Pearson χ2 test 
between the serum and plasma BDNF levels and the full 
scale IQ (FSIQ), verbal IQ (VIQ), and performance IQ 
(PIQ) (Table  3). The serum BDNF level was negatively 
correlated with the FSIQ (r = −0.39, p = 0.04) and VIQ 
(r = −0.50, p = 0.01), but not with the PIQ (r = −0.12, 
p = 0.56) (Table 3; Fig. 1). There was no significant rela-
tionship between plasma BDNF level and each IQ scale. 
Additionally, no correlation was found between the 
serum or plasma level of BDNF and the CCPT, ARS, 
CCTT or Stroop color-word test (Table  4). The total 
behavior problem and attention problem sections of 
the CBCL were positively related to plasma BDNF level 
[(r = 0.41, p = 0.03), (r = 0.44, p = 0.02)] (Table 5; Fig. 1). 
No relationship was found between plasma BDNF and 
social withdrawal, somatic complaints, anxiety/depres-
sion, social problems, Thought problems, delinquent 
behavior, aggressive behavior, internalizing or externaliz-
ing problems on the CBCL. No associations were found 
between serum BDNF level and any CBCL scores.
Discussion
This study is the first to investigate the association 
between BDNF levels and preschool children’s cognitive 
development in healthy subjects. We found that serum 
BDNF level was negatively associated with both full-scale 
and verbal IQ scores and that plasma BDNF level was 
negatively associated with CBCL attention and behavior 
problem scores.
BDNF is an important factor in neuro-development 
[3, 4]. Our results show that BDNF may play a role in 
intelligence, attention and clinical symptoms of pre-
school children with neuro-developmental disorders 
such as intellectual disability and ADHD. Higher periph-
eral BDNF concentration could be a biomarker of these 
states.
There are some reports of an association between 
BDNF and intellectual disability and of a general inverse 
correlation with intelligence in children [23–25]. Nel-
son et al. [23] reported elevated peripheral blood BDNF 
levels in neonates with intellectual disabilities than in 
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controls. They suggested that BDNF dysregulation may 
play a role in the development of intellectual disabil-
ity and that BDNF levels may be an early biomarker for 
identification of intellectual disability [23]. Miyazaki et al. 
[24] also found that children and adolescents (mean age: 
11.0 ± 5.9 years), diagnosed with an intellectual disabil-
ity, had higher blood BDNF levels than controls. They 
concluded that elevated BDNF levels may reflect an 
abnormal state in prenatal or early postnatal neuronal 
development [24]. However, Taurines et  al. [25] found 
no correlation between altered peripheral BDNF mRNA 
expression and BDNF protein concentrations in blood of 
children and adolescents with autism spectrum disorder.
Research has been conducted on cognitive function 
of BDNF over-expressed transgenic mice [10, 43]. Croll 
et  al. [43] found that BDNF over-expressed transgenic 
mice show significant impairment in learning (passive 
avoidance) and increase locomotor activities (maze arm 
entries) and hyper-excitability in the CA3 area of the hip-
pocampus. They suggested that excess BDNF may inter-
fere with normal learning and memory, and this result 
is due to too much excitability in the learning circuit or 
too much plasticity leading to synaptic refinement [43]. 
Cunha et  al. [10] also described that overexpression of 
BDNF in the forebrain may reduce learning and memory 
formation in mice. They proposed that the physiologi-
cal amount of BDNF is helpful in learning and memory, 
but an increased or decreased level of BDNF induces 
inhibitory and excitatory neurotransmission in the brain, 
causing loss of synaptic refinement and impairment of 
learning and memory [5].
Some researchers found a relationship between a poly-
morphism of the BDNF gene and cognitive functions in 
humans [44–46]. Egan et  al. [44] reported that the Val-
66Met polymorphism of the BDNF gene, valine (Val) to 
methionine (Met) substitution at codon 66, is related to 
poor episodic memory, abnormal hippocampal activa-
tion, abnormal intracellular trafficking and dysregulation 
of BDNF secretion in humans. fMRI research of the Val-
66Met polymorphism of the BDNF gene also described 
that the Val66Met polymorphism impacts memory 
related brain activity in the healthy humans. Addition-
ally, the Met allele of the BDNF Val66Met polymorphism 
is related to increased serum BDNF levels in adults [46]. 
Table 1 Demographic variables of the participants
Boys (n = 13) Girls (n = 15) Total (n = 28)
Age range 5.11–6.80 5.10–7.00 5.10–7.00
Age mean (SD) 6.12 (0.55) 6.19 (0.66) 6.16 (0.60)
Maternal age at pregnancy 29.54 (2.30) 29.73 (3.70) 29.65 (3.07)
Birth weight 3.23 (0.56) 3.04 (0.49) 3.13 (0.52)
Paternal education (n, %)
 12 years 3 (23.1) 3 (20.0) 6 (21.4)
 13–16 years 8 (61.5) 12 (80.0) 20 (71.4)
 Above 16 years 2 (15.4) 0 2 (7.2)
Maternal education (n, %)
 12 years 2 (15.4) 2 (13.3) 4 (14.3)
 13–16 years 8 (61.5) 13 (86.7) 21 (75.0)
 Above 16 years 3 (23.1) 0 3 (10.7)
Income (n, %)
 1–3 million/month 3 (23.1) 4 (26.7) 7 (25.0)
 3–5 million/month 8 (61.5) 9 (60.0) 17 (60.7)
 Above 5 million/month 2 (15.4) 2 (13.3) 4 (14.3)
Indirect smoking
 Yes (n, %) 8 (61.5) 9 (60.0) 17 (60.7)
Serum BDNF level mean (SD) (pg/ml)
 Age 5–6 24,063.33 (10463.72) 21,680.00 (6081.51) 22,871.67 
(8253.99)
 Age 6–7 19,562.14 (4843.85) 24,938.33 (10309.37) 22,586.25 
(8582.34)
Plasma BDNF level mean (SD) (pg/ml)
 Age 5–6 2546.08 (1971.05) 2827.75 (1725.49) 2686.92 (1772.26)
 Age 6–7 2728.82 (1605.08) 3205.25 (1682.22) 2996.81 (1612.25)
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Therefore, we need additional research about single 
nucleotide polymorphisms of the BDNF gene in children 
with higher serum levels of BDNF such as those in this 
study.
There are some controversial results about the 
relationship between BDNF and ADHD [20, 22, 
47]. Shim et  al. [22] found that children (mean age: 
8.8 ±  2.3  years), who are diagnosed with ADHD, have 
higher plasma BDNF levels than control children, and 
the severity of inattention problems have a positive 
Table 2 Psychometric properties of the participants
* P < 0.05
a Direction in which a change in score indicates good function
Favorable directiona Minimum Maximum Mean (SD)
Boys Girls
IQ
 FSIQ ↑ 86 124 106.31 (13.66) 107.40 (11.69)
 Verbal ↑ 80 127 105.31 (15.55) 105.67 (11.10)
 Motor ↑ 86 128 105.61 (12.85) 99.87 (28.06)
Computerized continuous performance test
Visual (T score)
 Omission error ↓ 40 135 72.61 (29.91) 60.73 (26.82)
 Commission error ↓ 40 117 69.46 (21.91)* 52.27 (9.76)*
Auditory (T score)
 Omission error ↓ 34 81 55.92 (14.73) 48.93 (11.16)
 Commission error ↓ 34 61 48.53 (7.03) 46.13 (8.45)
CCTT (T score)
 CCTT 1 time ↑ 18 65 35.46 (10.91) 36.67 (14.55)
 CCTT 2 time ↑ 40 143 85.08 (19.09) 80.93 (23.49)
 Inference index ↑ 40 67 51.23 (7.36) 52.87 (7.22)
Stroop (T score)
 Inference score ↑ 24 61 44.08 (7.79) 47.40 (9.93)
CBCL score (T score)
 Social withdrawal ↓ 18 100 47.46 (8.05) 44.80 (30.67)
 Somatic complaints ↓ 42 65 44.61 (6.66) 47.47 (7.35)
 Anxiety/depression ↓ 35 68 45.38 (9.07) 47.73 (10.63)
 Social problem ↓ 37 78 45.00 (8.95) 47.60 (10.38)
 Thought problem ↓ 45 58 45.92 (3.32) 47.47 (4.29)
 Attention problem ↓ 35 59 43.62 (7.92) 44.07 (7.79)
 Delinquent behavior ↓ 40 59 47.08 (6.20) 48.73 (6.42)
 Aggressive behavior ↓ 37 64 49.31 (6.76) 48.93 (7.96)
 Internalizing problems ↓ 33 71 44.38 (9.19) 46.73 (11.40)
 Externalizing problems ↓ 36 64 48.69 (6.75) 48.40 (8.04)
 Total behavior problems ↓ 30 71 45.38 (8.07) 47.80 (10.82)
ADHD rating scale
 Hyperactivity ↓ 0 10 4.92 (3.52)* 2.40 (2.80)*
 Inattention ↓ 0 13 4.00 (2.16)* 1.40 (2.29)*
 ARS total ↓ 0 23 8.61 (5.82)* 2.60 (2.56)*
Table 3 Correlation coefficient of IQ with BDNF levels














FSIQ ↑ −0.39 0.04 −0.21 0.30
VIQ ↑ −0.50 0.01 −0.02 0.91
PIQ ↑ −0.12 0.56 −0.33 0.08
Page 6 of 10Yeom et al. Child Adolesc Psychiatry Ment Health  (2016) 10:10 
correlation with plasma BDNF levels. They suggested 
that increased BDNF levels possibly reflect a compen-
satory mechanism in the response of abnormal and 
late brain maturation [22]. However, Scassellati et  al. 
[47] found no difference in serum BDNF level between 
ADHD children (mean age: 8.8 ± 2.3 years) and control 
children. Corominas-Roso et  al. [20] reported that 
adults with ADHD (mean age: 33.43  ±  8.99  years) 
have lower BDNF levels than control adults. They sug-
gested that low BDNF levels may contribute to the neu-
rodevelopmental deficit in ADHD [20]. A study have 
reported that the serum BDNF level increases over the 
Fig. 1 Scatter plot of BDNF levels with FSIQ, VIQ, CBCL total problem behavior, and attention problem score
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first several years and, then decreases after reaching 
adult levels in humans [26]. Therefore, more research 
is needed on the association between peripheral BDNF 
concentration and neuro developmental disorders in 
human development.
Animal studies have also reported controversial results 
about the relationship of BDNF with inattention and 
hyperactivity [43, 48–50]. Young adult transgenic mice, 
which over-express BDNF, have a tendency to spend 
more time being mobile [43], but BDNF knockout adult 
mice demonstrate more impulsive behavior, hyperactivity 
and learning deficiency [48–50].
Some studies have reported on the association between 
the BDNF gene and ADHD [51–53]. Of these studies, a 
cohort study on the association between the Val66Met 
polymorphism of BDNF and children with ADHD found 
that the Met allele is associated with ADHD symptoms, 
such as hyperactivity-impulsivity [53]. Another study 
found that the Valine allele of the Val66Met polymor-
phism of the BDNF gene is associated with the pathogen-
esis of ADHD [52]. Thus, additional studies are needed 
on the association between peripheral BDNF concentra-
tion and single nucleotide polymorphisms of the BDNF 
gene in children with ADHD.
Table 4 Correlation coefficient of ADS, ARS, CCTT, and STROOP with BDNF levels
a Direction in which a change in score indicates good function





Computerized continuous performance test (T score)
 Omission error (visual) ↓ 0.13 0.51 0.20 0.32
 Commission error (visual) ↓ 0.03 0.87 −0.19 0.35
 Omission error (auditory) ↓ 0.01 0.98 0.25 0.19
 Commission error (auditory) ↓ 0.08 0.70 −0.08 0.67
CCTT (T score)
 CCTT 1 time ↑ 0.18 0.36 −0.05 0.79
 CCTT 2 time ↑ 0.19 0.35 0.01 0.96
 Inference index ↑ −0.13 0.53 −0.10 0.60
Stroop test (T score)
 Inference score ↑ 0.02 0.90 0.19 0.34
ARS ↑
 Hyperactivity ↓ −0.13 0.50 0.20 0.30
 Inattention ↓ −0.10 0.62 0.29 0.13
 ARS total ↓ −0.11 0.59 0.28 0.16
Table 5 Correlation coefficient of CBCL with BNDF levels
a Direction in which a change in score indicates good function





Social withdrawal (T score) ↓ −0.17 0.34 0.18 0.35
Somatic complaints (T score) ↓ 0.05 0.80 0.27 0.17
Anxiety/depression (T score) ↓ −0.13 0.51 0.36 0.06
Social problem (T score) ↓ −0.08 0.97 −0.13 0.51
Thought problem (T score) ↓ −0.05 0.81 0.02 0.93
Attention problem (T score) ↓ −0.02 0.94 0.44 0.02
Delinquent behavior (T score) ↓ 0.06 0.77 0.12 0.53
Aggressive behavior (T score) ↓ −0.01 0.95 0.37 0.05
Internalizing problems (T score) ↓ −0.06 0.75 0.37 0.06
Externalizing problems (T score) ↓ −0.04 0.84 0.29 0.13
Total behavior problems (T score) ↓ −0.05 0.81 0.41 0.03
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Our study used serum and plasma levels of BDNF to 
investigate the relationships among peripheral blood 
BDNF level and childhood IQ and neurobehavior. In this 
study, serum BDNF level was related to VIQ and FIQ. 
However, plasma BDNF was not associated with VIQ 
and FIQ. Plasma BDNF levels were related to external-
izing problems and attention problems according to the 
CBCL, but not with serum BDNF levels. Many other 
studies have assessed the relationship between the serum 
or plasma level of BDNF and neuropsychiatric or devel-
opmental disorders [16, 19, 20, 22, 24]. However, there 
is still no standard method to measure peripheral BDNF 
levels. Additionally, the relationship between serum and 
plasma BDNF levels has not established. Yoshimura et al. 
[54] reported that plasma and serum levels of BDNF 
are positively correlated in healthy volunteers. How-
ever, Bocchio-Chiavetto et  al. [55] found no correlation 
between plasma and serum levels of BDNF in major 
depressive patients in a meta-analysis. Some researchers 
have suggested that plasma BDNF is a reliable indicator 
of brain BDNF levels because of the little influence of the 
BDNF that is stored in platelets [22, 56]. Other research-
ers have suggested that serum BDNF is a valid marker 
of brain BDNF because serum BDNF reflects the BDNF 
accumulated by platelets during illness or treatment peri-
ods [57]. Accordingly, we used two indicators, serum and 
plasma BDNF. Therefore, to use BDNF as a biomarker, a 
standardized method of measurement of BDNF and the 
source of peripheral BDNF is needed.
This study has some limitations that must be consid-
ered. First, we did not assess our subjects with structured 
interviews to rule out psychiatric illnesses. However, we 
assessed their intelligence and psychiatric history using 
a standardized intelligence scale and questionnaire. Sec-
ond, we assessed the correlation between peripheral 
blood BDNF and intelligence and psychiatric problems 
in the same group. Therefore, we could not compare the 
absolute peripheral BDNF level of patients with ADHD 
or other DSM-5 neurodevelopmental disorders. Third, 
this study was a cross-sectional study. In BDNF over-
expressing mice, memory retention was impaired in 
younger animals, but not in older ones [10]. Thus, a long-
term follow up study on blood BDNF levels and psycho-
pathologies is needed. Last, we included 28 preschool 
children, and higher number of subjects would increase 
statistical power.
Conclusions
Our results suggest that high peripheral concentration of 
BDNF is related to intelligence, inattention and behavio-
ral problems. Further studies on BDNF metabolism are 
required, using a standardized measurement method for 
BDNF ascertainment, with parallel genetic analysis of 
BDNF gene polymorphisms, with a robust sample size and 
with long-term follow-up are needed to further validate 
this line of research and to clarify the role and relevance 
of differences in peripheral BDNF as a potential biomarker.
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